It is made available under a CC-BY-NC-ND 4.0 International license.

### 1 **TITLE PAGE**<br>2 **Uncovering**



- 7
- 8
- 
- 9
- 10  $^{-1}$ Science & Technology Policy Studies, METU, Turkey
- 11 <sup>2</sup> Medical Genetics Department, ESOGU Faculty of Medicine, Turkey
- <sup>3</sup> Child Health and Diseases Department, Faculty of Medicine, ESOGU Faculty of Medicine,
- 13 Turkey
- 14
- 
- 15
- 16
- 17
- 
- 18
- 19
- 20
- 21 ∗Correspondence:
- 22 Mehmet Arda Temena
- 23 METU, Science and Technology Policy Studies
- 24 Ankara, Turkey
- 25 Mail: arda.temena@metu.edu.tr
- 26 Tel: +905543897331
- 27
- 28
- 29

It is made available under a CC-BY-NC-ND 4.0 International license.

30

# 31 **ABSTRACT**<br>32 Myocardial o

Myocardial defects, originating from disruptions in genes affecting mitochondrial 33 proteins interacting with others, have received limited research attention. In our study 34 involving 27 pediatric cardiomyopathy patients, we explored mitochondrial and nuclear genes 35 for four main cardiomyopathy subtypes. Sequencing cardiomyopathy-associated genes in 36 patients was followed by whole mtDNA sequencing in these individuals, with 31 healthy 37 pediatric controls for the latter part. Our findings uncovered significant pathogenic variants: 38 MYH7 variants in three hypertrophic cardiomyopathy cases, a notable TNNC1 variant inherited 39 interestingly in an autosomal recessive manner in two related restrictive cardiomyopathy 40 patients, and a pathogenic TRDN variant in a left-ventricular non-compaction patient. Both a 41 variant in FOXRED1, functioning in mitochondrial complex I stability, and a MT-CO1 variant 42 were detected in two siblings, influencing early onset together. Additionally, a novel MT-RNR1 43 variant (m.684T>C) in one case might explain the phenotype. Our study highlights how both 44 mtDNA and nDNA variants could have interconnected roles in understanding cardiomyopathy 45 genetics. This study emphasizes that the functional studies are needed to recognize this dual 46 relationship within bioenergetic pathways in cardiac muscle.

47 INTRODUCTION

48 In pediatric population, heart failure can occur when normal myocardium is mostly 49 damaged by an inflammatory or infectious process like myocarditis, metabolic disorders that 50 cause cardiomyopathy, and solely due to hemodynamic imbalances because of syndromic or 51 non-syndromic congenital structural defects(Iaizzo, 2015). Although cardiomyopathies one of 52 the leading causes of heart failure and sudden cardiac death among the young all over the 53 world, present molecular studies are not yet to be concluded and therapeutic approaches are 54 used mostly to relieve the symptoms of the disease except heart transplantation at the end 55 stage of the disease(Lipshultz et al., 2019; Sanganalmath & Bolli, 2013). Therefore, pediatric 56 cardiomyopathies require an elaborative and multidisciplinary evaluation approach starting 57 from diagnosis to prevent rapid progressive case of the disease(Lee et al., 2017).

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

58 The prevalence of pediatric cardiomyopathy subtypes (classification made by American 59 Heart Association, European Society of Cardiology and World Heart Federation(Elliott et al., 60 2007; B. Maron et al., 2006) (Arbustini et al., 2014)) differs based on the accuracy of diagnostic 61 evaluations and classification criteria, and the rarity of the disease complicates data collection. 62 Indeed, it has been reported that certain genotypes may correspond to specific types of 63 cardiomyopathies(J. W. McKenna et al., 2017)'(Tobita et al., 2018).

64 It is known that some variants in some certain genes known to be directly associated 65 with cardiomyopathies may have non-cardiac systemic or metabolic manifestations(Fiorillo et 66 al., 2016; Jhang et al., 2016). Given the complexity of genetic factors involved, there is limited 67 but growing understanding of the portion of heritability that remains unexplained interactions 68 between genes, and factors that modify the progression of each type of cardiomyopathy(Lee et 69 al., 2017). Pediatric cardiomyopathies can result from various genetic alterations, including 70 metabolic dysfunctions like a diabetic mother and the occurrence of hypertrophic 71 cardiomyopathy-HCM in some storage disorders. The genetic basis for isolated pediatric 72 cardiomyopathies may overlap with those found in adult cases, but the mode of inheritance can 73 be variable and may also occur due to solely *de novo* mutations(Jhang et al., 2016; Lee et al.,<br>74 2017). Recent research has shown that genetic factors adapting to various inheritance patterns 74 2017). Recent research has shown that genetic factors adapting to various inheritance patterns 75 have a significant role in cardiomyopathy which helps to determine a correct 76 classification(Hershberger et al., 2013; Jacoby & McKenna, 2011). Among those, although much 77 smaller than the nuclear genome, studies on the mitochondrial genome also have become the 78 most popular subject not only for cardiomyopathies and particularly for cardiomyocytes(Dorn, 79 2015) but also for investigating other complex diseases(Tashiro, 2018).

80 In this study, we sought to investigate the genetic profile of pediatric patients with 81 primary cardiomyopathy from Turkey's Central Anatolia Region by sequencing cardiomyopathy-82 related genes and whole mtDNA sequencing. Figure 1 provides a graphical abstract illustrating 83 the design of the study and significant results. There is a graphical abstract for this study. 84 Additionally, the aim was to assess patients in the primary cardiomyopathy group given the 85 crucial role that mitochondrial proteins play in energy metabolism and bioenergetics in relation 86 to the heart along with nuclear DNA (nDNA) variants.

 $\frac{3}{3}$ 

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .



87

88 Figure 1. Genetic proming in pediatric cardiomyopathies. This graphical abstract 89 illustrating the comprehensive genetic profiling approach used in this study to sequence 90 cardiomyopathy-related genes and whole mitochondrial DNA in pediatric patients with 91 cardiomyopathy. e h

### <sup>92</sup> RESOLIS

#### 93 Clinical evaluation

94 All detailed clinical manifestations and other related information are analyzed and wil l

95 be available with **Supplementary Table S1** upon reasonable request to corresponding author.

#### 96 Cardiomyopathy-associated variants

97 A total of 269 exonic variants were identified after filtering (Figure 2B). Out of these e 98 variants, 164 (60.97%) were nonsynonymous SNVs whereas 98 of them (36.43%) were e 99 synonymous. There were also three frameshift deletions (1.12%) and three non-frameshift t 100 deletions (1.12%), and one stop-gain variant (0.37%). Following the variants are classified by y 101 gene, and the count and percentage of variants found in each gene are given, the total number r 102 of variants is 269, of which 12 (4.5%) are homozygous and 257 (95.5%) are heterozygous. The e 103 most frequent variants are found in the gene TTN with 91 (33.8%) variants and the second one e

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

104 is in PLEC gene with 24 (8.9%). A scatterplot that summarizes the variants grouped by genes 105 and corresponding genotypes was given in **Supplementary Figure S1**. The expression levels of 106 these genes in the heart were examined by the GTEx database, and the resulting plot is 107 presented in Figure 2C. This analysis revealed four clusters for the genes in which some variants 108 detected and among them, MYH7, MYBP3, TNNT2 and TNNC1 is highly expressed.

109 In the cohort of 27 pediatric patients with cardiomyopathy, 62 variants were identified 110 after evaluation and filtering as VUS or Pathogenic. All these variants grouped by disease 111 subtype can be found in Figure 2D. Out of these variants, 57 (91.9%) were heterozygous and 112 five of them (8.1%) were homozygous. Most variants were nonsynonymous SNVs, 55 (88.7%) of 113 which 5 were homozygous. There were also 2 variants each of frameshift deletions (3.2%) and 114 non-frameshift deletions (3.2%), and one stop-gain variant (1.6%). Two variants were 115 Synonymous SNV (3.2%). Out of 62 variants, 5 (8.1%) were pathogenic, of which 3 were 116 nonsynonymous SNV in MYH7 gene leading to HCM, 1 was nonsynonymous SNV in TNNC1 117 leading to RCM, 1 was frame shift deletion in TRDN leading to LVNC. The remaining 57 variants 118 (91.9%) were concluded as VUS.

119 Specifically, patient-8, patient-13, and patient-14 have a pathogenic variant in the MYH7 120 gene, and they are diagnosed with HCM (Supplementary Figure S2). Patient-21 has a 121 pathogenic variant in the TRDN gene and patient 9-10, who were mother side cousins and 122 diagnosed with RCM have a pathogenic variant in the TNNC1 (Supplementary Figure S2).

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .



123<br>124 124 Figure 2. General demographic reatures of the patients and the study highlights. At 125 Distribution of number of patients and control group, and mean age (for mtDNA group) over 126 cardiomyopathy subtypes There are four distinct primary cardiomyopathy group (HCM;<br>127 by estacle conditions and proportions of the dileted conditional problem DCM; acctuative 127 hypertrophic cardiomyopathy, DCM; dilated cardiomtyopathy, RCM; restrictive e 128 cardiomyopathy, LVNC, left ventricular non compactionni). B. Functional consequences of 129 nDNA variants from patients' group is given accross their genotype or heterozygosity or<br>120 heterographic C European build fill Conductive accieration to the ted genes in beachtisers. 130 homozygosity. C. Expression level of VUS and pathogenic variant-detected genes in heart tissue . 131 The graph was generated using Genotype-Tissue Expression (GTEx) website. The genes were e 132 colored according to their expression level clusters (Very high expression; red, high expression;<br>133 colored according to their expression; relieve level expression; recently Departmentation of MIC and 133 blues, moderate expression; yellow, low expression; green). D. Representation of VUS and 134 pathogenic variants over disease subtypes and genotypes. Each gene was colored according to 135 their corresponding expression clusters. r restrictive u<br>o

#### 136 Mitochondrial variants

137 Results show that in a cohort of 27 pediatric patients with cardiomyopathy, the analysis s 138 of mitochondrial variants revealed that 695 alterations were found in the cardiomyopathy (CM) )

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

139 group, while 315 unique alterations were found in the control group. Examination of different t 140 disease groups showed that the highest frequency was found in HCM, with 337 variants, , 141 followed by LVNC with 164 variants, DCM with 133 variants, and RCM with 61 variants. On the e 142 other hand, ratio of variants over patients per disease subgroup are DCM at 26.6, HCM at 22.0, , 143 LVNC at 31.8 and RCM at 30.5. Analysis of the genetic alterations revealed that the most t 144 common type of alteration was SNPs, with 677, followed by insertions (INS) with 10, multi-- 145 nucleotide polymorphism (MNP) with 3, and Deletion (DEL) with 5 occurrences. In Figure 3, the e 146 distribution of all variants among the different disease subtypes is shown in the patient group . 147 Additionally, all variants found in patients with control group and only control group were also o 148 plotted (Supplementary Figure S3 and S4, respectively). However, we evaluated variants that t 149 are found only in patient group after comparison with control group.



150

151 Figure 3. Solar Plot of Mitochondrial Variants in Cardiomyopathy Subtypes . 152 Mitochondrial variants across cardiomyopathy subtypes from mtDNA sequencing are displayed 153 on a solar plot. An identified variant is represented by each dot. According to the plot legend, u<br>J  $\overline{\phantom{a}}$ 

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

154 the inner dashed rings of the plot represent the level of heteroplasmy, and dots are colored 155 according to genes at that region. The position of the mitochondrial base pair is shown on the 156 X-axis. Red line represents a line for specified 90% heteroplasmy level.

157 Results showed that homoplasmic variants were the most common, with 688, while 158 heteroplasmic variants were found in 7 occurrences. Seven variants detected in only five 159 patients showed heteroplasmic features. These are m.16184C>T detected in patient-16 (34%), 160 m.8286T>C detected in patient-18 (37.6%), m.3918G>A detected in patient-22 (30%), m. 161 9053G>A and m.10045T>C (87.5% and 92.3%, respectively) and m.16189Tdel (66.1%) detected 162 in patient-26. All other variants detected in mtDNA show homoplasmic (≥95%) feature. After 163 filtering of all variants, mtDNA sequencing results revealed that 34 transition were found, one 164 insertion was detected. In Figure 4A, functional consequences and disease subtypes of filtered 165 mtDNA variants were given. The mitochondrial loci were examined, revealing a total of 33 166 unique variants (35 in total) across two rRNA and ten protein coding genes. The 16S locus had 167 the highest number of alterations with six variants, followed by COI with five variants, 12S and 168 ND5 with four variants each. Three genes had three variants each: ATPase6, COIII, and Cytb. 169 Two genes had two variants each: ND4, and ND6. Finally, three genes had only one variant 170 each: ND2, ND3, and ND4L. Also, the mitochondrial haplogroups of patients and controls in the 171 study were analyzed (Figure 4B). The most common major haplogroups among patients were H, 172 J, and U while the most common haplogroups among controls were H and U. There was no 173 statistically significant consequence between control and patient group with respect to 174 haplogroups. Other major haplogroups are Y, W, K, M, V, T, X, R, C and N. Additionally, another 175 plot (Supplementary Figure S5) was provided where mitochondrial variants were classified 176 according to the patients.

It is made available under a CC-BY-NC-ND 4.0 International license.



177

178 Figure 4. Overall identified and filtered mtDNA Variants and Pedigree analysis of the<br>179 patients. A. Filtered variants across mtDNA genes and functional consequences of these 179 **patients. A.** Filtered variants across mtDNA genes and functional consequences of these 180 variants. Alteration type and the subtype of the patient determines the color and the shape, variants. Alteration type and the subtype of the patient determines the color and the shape, 181 respectively. Conservation score line was given as red dashed line. Variants that are indicated 182 by arrows are either pathogenic or likely pathogenic which are depicted as black or pink color, 183 respectively. **B.** mtDNA haplogroups distribution for the study cohort. C. Three pedigrees are<br>184 given for patients, but detailed pedigrees are available on request to corresponding authors. given for patients, but detailed pedigrees are available on request to corresponding authors.

It is made available under a CC-BY-NC-ND 4.0 International license.

185 Haplogroup subtypes as well as a comprehensive list of all filtered mtDNA and nDNA 186 variants with their pathogenicity predictions were provided in Supplementary Table S2A, Table 187 S2B, and Table S2C, respectively, but patient information is removed and available on request.

188 **DISCUSSION**<br>189 Looking at the

Looking at the distribution of clinical and demographic characteristics among the 190 patients, we see parallel results with a comprehensive study conducted among pediatric 191 cardiomyopathy patients in 2022(Ware et al., 2022). Although the 27% positive family history 192 rate (Supplementary Table S1A) among our patients may not directly correspond to the 36% 193 rate in that study, this could be due to the filters used in our study and the low number of 194 patients in our study. In addition, the age of diagnosis was found to be high on average in our 195 patient group. While this could be due to asymptomatic patients receiving a diagnosis only 196 during routine check-ups or other illnesses, socioeconomic factors that affect the access of 197 young children/families to healthcare services in the country should not be ignored. Moreover, 198 one another comprehensive study revealed positive association between cardiomyopathy 199 subtype and age at diagnosis(Bagnall et al., 2022). Similarly, the diagnosis of HCM was made at 200 later ages compared to other subtypes, while in cases of DCM, it was made before the age of 3 201 in our study. However, the low number of patients included in the study and the rarity of the 202 disease may be a reason for the discrepancy in the mean age of diagnosis for LVNC and RCM 203 subtypes.

#### 204 Hypertrophic cardiomyopathy

205 Out of 15 HCM patients, either a VUS or pathogenic variant was detected in all of them. 206 In three HCM patients (20% of HCM patients), a pathogenic variant was detected in the MYH7 207 gene, which is consistent with the information that the variants found in HCM children are most 208 commonly in the MYH7 gene(Ware et al., 2022). Among them, patient-13 and patient-14 was 209 heterozygous for a nonsynonymous single nucleotide variant (SNV) in the MYH7 gene as 210 p.Arg403Gln and p.Arg719Trp, respectively. Additionally, patient-8 was found to be 211 homozygous for a nonsynonymous SNV in the MYH7 gene (p.Asp928Val). In fact, MYH7 212 mutations can lead to a direct effect of delayed relaxation due to abnormal myosin function at 213 the molecular level, which in turn causes inefficient energy use at the myocardial tissue

It is made available under a CC-BY-NC-ND 4.0 International license.

214 level(Alamo et al., 2017; Nguyen et al., 2022; Toepfer et al., 2020). In patients with MYH7, the 215 most common symptom reported was palpitations in one study(Velicki et al., 2020) but other 216 symptoms of HCM are fatigue, chest pain, and syncope(B. J. Maron, 2018). These patients were 217 assigned to different mitochondrial haplogroups, H, U and W respectively.

218 In addition to the MYH7 variants mentioned, all variants identified in patients with HCM 219 have been classified as variants of unknown significance (VUS). A previous functional study of a 220 missense mutation in the MYL3 gene, previously classified as VUS, suggested that the mutation 221 had benign effects(H. Guo et al., 2021). However, a homozygous alteration 222 (MYL3(NM\_000258.3):c.170C>A/p.Ala57Asp) with damaging prediction results and the high 223 expression of the gene in left ventricular (Figure 2C), and the presence of highly conserved a 224 mitochondrial variant in MT-RNR2 (m.2060A>G) in the patient-11 may possibly contribute to 225 the phenotype altogether. Moreover, a missense variant in TNNT2 gene is identified in patient-226 17 with asymmetric septal hypertrophy (TNNT2(NM 001276345.2):c.691A>G/p.Ile231Val). It 227 affects the TNNT2 gene, which codes for cardiac troponin  $T$  (cTnT), a protein that is part of the 228 troponin complex found in heart muscle and plays an important role in regulating calcium as 229 well as thin actin filament contractility and expressed highly in left ventricle (Figure 2C). Apart 230 from this variation, this patient has other missense variants in TTN, PLEC and LAMA2 gene as 231 well as in MT-ND6 and MT-CYB gene latter of which has high conservation rate (78%). One 232 study by Rippol-Vera et al. suggests that some TNNT2 variants may interact with other variants 233 associated with other cardiac diseases or pathways, influencing the way the disease develops 234 and the prognosis(Ripoll-Vera et al., 2016). This suggests that further studies are needed to 235 confirm this, and this patient's variants could be a fine model for a functional study.

236 Furthermore, there are some publications linking RBM20 to cardiomyopathy(W. Guo et 237 al., 2012; Lennermann et al., 2020). Additionally, a study by Zaragoza et al. in 2011, which 238 examined the relationship between mtDNA and cardiomyopathy, classified a variant on MT-239 ND4 as highly likely to be pathogenic(Zaragoza et al., 2011). In our study, when *in silico* analysis<br>240 scores for pathogenicity were considered for the variant with its high conservation score on 240 scores for pathogenicity were considered for the variant with its high conservation score on 241 MT-ND4 (m.11084A>G), it is possible that this variant may have created a pathogenic situation 242 in patient-2, in combination with RBM20 variant (RBM20(NM\_001134363.3):c.1745A>T /

It is made available under a CC-BY-NC-ND 4.0 International license.

243 p.Asn582Ile). Next, patient-3 and patient-4 are siblings who have been diagnosed with HCM. 244 Both patients were found to have heterozygous variants in the TTN gene, which is known to be 245 associated with HCM. Additionally, patient-3 and-4 were also found to have heterozygous 246 missense variant in the FOXRED1 (FOXRED1(NM\_017547.4:c.658C>T)/p.Pro220Ser). Some other 247 variants in ALMS1 and ABCC6 genes, which were not directly related with primary 248 cardiomyopathy though, were found in patient-4 whereas patient-3 only has additional TTN 249 variants. Therefore, it is not clear how these variants are contributing to the development of 250 HCM in these patients and further research is needed to understand the relationship between 251 these genes and HCM. On the other hand, these siblings also have highly conserved 252 mitochondrial variants in MT-CO1, concluded as pathogenic *in silico* analysis (m.6345T>C) and<br>253 MT-CO3 (m.9966G>A) gene, with the conservation score of 100% and 82%, respectively. The<br>254 cytochrome c oxidase, also 253 MT-CO3 (m.9966G>A) gene, with the conservation score of 100% and 82%, respectively. The cytochrome c oxidase, also known as Complex-IV, is the enzyme in the electron transport chain 255 that transfers electrons from cytochrome c to molecular oxygen. It is made up of 14 subunits in 256 humans, but only two of them, MT-CO1 and MT-CO2, have catalytic activity but MT-CO3 do not 257 have this function. Also, one another mitochondrial gene FOXRED1, found in the list of 258 mitochondrial proteins in Mitocarta 3.0(Rath et al., 2021), some variants of which is associated 259 with mitochondrial Complex-I deficiency and related to cardiomyopathy(Mukherjee & Ghosh, 260 2020), encodes structural subunits and assembly factors. Co-existence of these two variants in 261 FOXRED1 and MT-CO1 could explain the early-onset etiology of HCM in these siblings whose 262 father has also has late-onset HCM and pedigree is given in Figure 4C as some variants inherited 263 together can cause diverse group of mitochondrial diseases(Fernandez-Vizarra & Zeviani, 2021; 264 Vercellino & Sazanov, 2022). Identified variants in MT-CO1 and FOXRED1 genes can be 265 associated with early-onset cardiomyopathy, emphasizing their relevance within mitochondrial 266 diseases in children, especially in the context of complex I disorders (Koopman et al., 2016).

267 Although recent studies revealed that DTNA variants were commonly found in patients 268 with the left ventricular trabeculation and non-compaction phenotype which are also some 269 manifestations of Barth syndrome(Bottillo et al., 2016; Geske et al., 2018; Moric-Janiszewska & 270 Markiewicz-Łoskot, 2008), they were not sufficient to fully explain the clinical presentation of 271 patient-1 (DTNA(NM\_001390.4):c.165A>G/p.Ile55Met) with HCM in addition to presence of a

It is made available under a CC-BY-NC-ND 4.0 International license.

272 TTN variant. In patient-12, variants in the CTTNA3, TBX5 and PLEC genes were classified as VUS. 273 Also, a missense variant in the alpha-T-catenin gene (CTNNA3) is also identified, which plays a 274 role in how cells stick together and is present in both the heart and brain. This variation may be 275 linked to a type of heart disease called arrhythmogenic cardiomyopathy, but there is no proof 276 that it is directly associated with HCM (B. Li et al., 2020). However, TBX which specifically plays 277 an important role in cardiac contraction (Reactome ID: R-HSA-5576891.1) and the patient's 278 other variant on PLEC, there may be an explanation for the patient's phenotype if a functional 279 study is conducted harboring these mutations even though TBX5 and PLEC are not directly 280 involved in primary cardiomyopathies (OMIM ID: 601282 and 601620). In addition, patient-22, 281 has five variants, three of which are found in the TTN gene. The remaining two variants are in 282 the DMD and RYR2 genes, and it is not clear how they contribute to the patient's condition 283 without further study of the patient's family. Similarly, patient-25 also has three VUS located in 284 the TTN, ALMS1, which is not directly involved in primary isolated cardiomyopathies, and 285 SLC22A5 genes, all of which are missense mutations. Lastly, patient-6 has a homozygous 286 nonsynonymous SNV in the KCNJ2 gene. Screening the KCNJ2 gene in individuals is clinically 287 significant in syndromic cases because a significant proportion of individuals with pathogenic 288 variants in this gene present with distinct symptoms however this does not explain isolated 289 phenotype of this patient's HCM. Despite being found in patients with both sustained 290 monomorphic ventricular tachycardia (SMVT) and DCM, there is currently insufficient evidence 291 to establish a link between the KCNJ2 gene variant and HCM(Kimura et al., 2012; Ortega et al., 292 2016).

#### 293 Dilated cardiomyopathy

294 In total, patient-18 has variants in the MT-CYB, 16S (MT-RNR2), TTN, DMD, and PLEC 295 genes. Patient-23 has variants in the MT-COI and MT-ND6 genes. Next, patient-24 has two 296 variants in the mitochondrial 16S locus. Additionally, patient-5 has mtDNA variants in the 16S 297 and MT-ND4L genes along with one in BAG3 gene, and patient-15 had only nDNA variants in the 298 JPH2 and PCCA genes latter of which associated with propionicacidemia.

299 Nonsyndromic DCM is a type of heart condition that is typically inherited in an 300 autosomal dominant way. However, there are some subtypes of this condition, such as JPH2-

It is made available under a CC-BY-NC-ND 4.0 International license.

301 and TNNI3-related nonsyndromic DCM, that can also be inherited in an autosomal recessive 302 way. When a proband is found to have one of the genetic variants known to cause this 303 condition, it is important to consider the risk of DCM for other family members who may also 304 carry the same genetic variant to explain underlying phenotype (Hershberger & Jordan, 2022). 305 Based on available research, it seems that when there is a loss of function in the JPH2 gene 306 passed down through the autosomal recessive method, it is linked to a severe form of DCM that 307 presents at an early age. On the other hand, when the pathologic variants of JPH2 are inherited 308 in an autosomal dominant manner, it leads to a condition called HCM through a mechanism 309 known as dominant negative effect (Parker et al., 2023). Nevertheless, it may not be sufficient 310 to explain the clinical presentation without conducting a family analysis, but it may also be 311 necessary to evaluate it in co-occurrence JPH2 variant 312 (JPH2(NM\_020433.5):c.1879A>G/p.Ile627Val) with a PCCA variant 313 (PCCA(NM\_000282.4):c.522G>A/p.Met174Ile) found in in the patient-15. Other studies have 314 shown that certain pathogenic variants can explain the clinical presentation even in 315 combination with other variants in other genes(Riemersma et al., 2017; Sabater-Molina et al., 316 2016).

317 For patient-18, it is challenging to determine the role of pathogenic variants in the TTN 318 gene in DCM because a significant number of controls from other studies also have truncating 319 variants in this gene and not all families with DCM have a clear pattern of inheritance of the 320 variants. Additionally, some research have shown that the truncating variants found in 321 individuals with DCM tend to cluster in a specific region of the protein encoded by the TTN 322 gene. So far, missense variants in the TTN gene have not been linked to the development of 323 DCM (Herman et al., 2012; Norton et al., 2013; Roberts et al., 2015). In addition to other 324 alterations in nDNA of this patient, a particular alteration in a specific region of MT-CYB 325 (m.15497G>A), which is highly conserved across different forms and species, has been 326 identified. One study looked at blood and heart tissue samples from people who died suddenly 327 from CM and 151 healthy controls. They found that a specific genetic variation (m.15497G>A) in 328 the MT-CYB gene occurred more frequently in the sudden cardiac death cases. This variation is

It is made available under a CC-BY-NC-ND 4.0 International license.

329 in a highly conserved part of the gene (89%), and the researchers suggest that it may be 330 associated with reduced energy metabolism (Kobayashi et al., 2011).

331 Mitochondrial variants at the region whose conservation score bigger than 70% in 332 patient-5 and patient-24 is in MT-RNR2 (m.2294A>G and m.3159AA>T, respectively), in MT-CO1 333 (m.6261A>G) for patient-23, which are the only changes in these patients. Some studies 334 investigated variants in rRNA and found that some pathogenic variants have been associated 335 with certain diseases in literature(Elson et al., 2015; Gutell et al., 2002; Smith et al., 2013). 336 However, there is currently no tool available to evaluate human-specific MT-RNR1 and MT-337 RNR2 variants in silico other than methods like those used to study evolutionary ribosomal RNA 338 pathogenicity like HIA (Vila-Sanjurjo et al., 2021). It is suggested that mitochondrial rRNA 339 mutations can affect mitochondrial translation and can cause or modify the phenotype of 340 cardiomyopathy(D. Li et al., 2019; S. Li et al., 2018; Santorelli et al., 1999). On the other hand, it 341 is reported that BAG3 is essential for maintaining mitochondrial homeostasis, and changes in 342 BAG3 expression have an adverse effect on cardiomyocyte function, which can shape the clinic 343 of patient-5 with its mtDNA variants (Tahrir et al., 2017; Wang et al., 2023). A previously 344 reported missense mutation in the MT-CO1 gene has been suggested to have a high likelihood 345 of being associated with myopathy (Zaragoza et al., 2011). It has been noted that MT-CO1 plays 346 a role in Complex IV formation and is important in the context of cardiomyopathies (Huigsloot 347 et al., 2011). Since it is not possible to overlook the cardiac involvement of myopathy, it is not 348 surprising that an effective change in this gene could cause cardiomyopathy. However, ClinVar 349 submissions of these variants are likely benign regarding other mitochondrial diseases, 350 maternal segregation analyses are still needed to clarify the inheritance for DCM.

#### 351 Left-ventricular non-compaction

352 Research has shown that in nearly half of LVNC cases, there are variants found mostly in 353 genes associated with other cardiac-related conditions. However, it is unclear what the 354 definition of the phenotype or the pathogenicity of these variants is (van Waning et al., 2018). 355 Additionally, it has been suggested that isolated LVNC may be a symptom or a phenotype 356 rather than a distinct disease, as few genetic variants was found in cases that also had other 357 cardiomyopathy symptoms (Hershberger et al., 2017; Miller et al., 2017).

It is made available under a CC-BY-NC-ND 4.0 International license.

358 For the five cases of LVNC, one pathogenic heterozygous frameshift deletion was found 359 in TRDN gene and other variants were classified as VUS in TSFM, MYH7, TTN, AGL, TRDN, RYR2, 360 RBM20, BAG3, DSP and LARGE2 genes. Patient-21 who has a frameshift deletion in TRDN 361 (TRDN(NM\_006073.4):c.423delA/p.Glu142fs) in TRDN gene, classified as pathogenic, but 362 homopolymer nature of the region requires Sanger sequencing to conclude the disease-variant 363 association. Also, this patient has a VUS in RYR2 gene that can contribute to the phenotype 364 because TRDN is a protein that connects the RYR2 gene with some other cardiometabolic 365 proteins and plays a role in regulating the release of calcium in the sarcoplasmic reticulum, 366 which is showed in a functional study (Rebs, 2021).

367 A frameshift deletion in MYH7 (MYH7(NM\_000257.4):c.575delT/p.Ile192fs), a 368 heterozygous stop variant in TSFM (TSFM(NM\_001172696.2):c.5C>A/p.Ser2\*), and a missense 369 variant in TTN were identified in patient-19. Some biallelic mutations associated with MYH7 370 have been reported to be associated with LVNC (Kolokotronis et al., 2019). There are also 371 publications linking TSFM gene with mitochondrial cardiomyopathies (Takeda, 2020). Thus, 372 although these mutations are expected to explain the phenotype to some degree, they are 373 classified as VUS. On the other hand, a mutation in TSFM encoding one of the mitochondrial 374 translation prolongation factors has been associated with isolated fatal neonatal HCM in one 375 family (Smeitink et al., 2006). Considering the clinical overlaps of HCM and LVNC (Lin et al., 376 2021), it is appropriate to re-evaluate these variants after segregation analysis. In addition, two 377 missense variants in TTN and one in RBM20 378 (RBM20(NM\_001134363.3):c.3249G>C/p.Glu1083Asp) were found in patient-26 and classified 379 as VUS. Similarly, many studies have reported that LVNC is caused by mutations in a RBM20. 380 One is the first to report that reduced activity of RBM20 can lead to LVNC due to TTN mis-381 splicing. Some other studies also revealed that truncating TTN variants are the leading cause for 382 LVNC and introduce variants in RBM20 as a novel etiopathology for LVNC (Anna et al., 2020; 383 Sedaghat-Hamedani, Haas, Zhu, Geier, et al., 2017; Sedaghat-Hamedani, Haas, Zhu, 384 Kayvanpour, et al., 2017). One another study also presented a patient with an early onset DCM 385 carrying a combination of (likely) pathogenic TTN and RBM20 mutations (Gaertner et al., 2021). 386 Additionally, one research found that the splicing of RBM20 target genes is affected in the

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

387 mutation carrier and revealed RBM20 haploinsufficiency presumably caused by the frameshift 388 mutation in RBM20. The results showed that the same variant in RBM20 can cause DCM, with 389 or without the LVNC phenotype (Sun et al., 2020). Understanding of the variant pathogenicity 390 across the RBM20-coding transcript is needed with segregation analysis for this patient and 391 others who have LVNC, and it's important for the future management of the disease. For 392 patient-27 who has three heterozygous missense variants each in DSP 393 (DSP(NM\_004415.4):c.3226C>T/p.Leu1076Phe), BAG3

394 (BAG3(NM\_004281.4):c.461T>G/p.Val154Gly) and and LARGE2 395 (LARGE2(NM\_001300721.2):c.385C>T/p.Leu129Phe), there is no clear explanation for the 396 phenotype without a family study. However, a specific truncating variant was reported in the 397 DSP gene is associated with the development of LVNC and severe early-onset heart failure even 398 though it is typically associated with DCM (Williams et al., 2011). The study findings reveal a 399 range of genetic variations in individuals with LVNC. The various genetic makeup may account 400 for the different clinical presentations observed in patients with LVNC.

401 In addition to missense TTN variants, three variants that have high conservation scores 402 in MT-CO1 (m.6546C>T), MT-CO3 (m.9948G>A) and MT-RNR1 (100%, 96%, 73%, respectively) 403 were detected in patient-20 whose pedigree is given in Figure 4C, and the variant in MT-RNR1 404 (m.684T>C) could not be found in the databases and seems a novel homoplasmic variant. 405 Patient's one sibling died of an unknown cause and another sibling also manifests LVNC and 406 some other dysmorphic findings caused by additional *de novo* microdeletion revealed by<br>407 microarray analysis. In a study that investigates the mitochondrial rRNA encoding the 12S<br>408 subunit of mitochondrial rRNA, i microarray analysis. In a study that investigates the mitochondrial rRNA encoding the 12S subunit of mitochondrial rRNA, it was stated that LVNC may be associated some variants in this 409 locus. However, they also suggested that the 12S rRNA, MT-RNR1, would have a more smaller 410 effect than other mutations found that changed its conformation (Tang et al., 2010). One study 411 suggests that analyzing mtDNA sequence variants in myocardial tissue samples could provide 412 useful information for understanding the causes of LVNC (Liu et al., 2013). In this study, 413 researchers found that the mtDNA copy number in the myocardium of LVNC patients was lower 414 compared to healthy controls. This lower mtDNA copy number, in combination with

It is made available under a CC-BY-NC-ND 4.0 International license.

415 morphological abnormalities of mitochondria, suggests that there may be dysfunction of the 416 mitochondria which may play a role in the development of LVNC.

#### 417 Restrictive cardiomyopathy

418 Patients-9 and patient-10, who are cousins on their mother's side, whose pedigree is 419 shown in Figure 4C, were found to have a homozygous pathogenic variant in the TNNC1 gene 420 (TNNC1:p.8A>V). The TNNC1 gene codes for troponin C protein, which is responsible for 421 contractility in the heart muscle and is one of the three members of the complex troponin 422 family. Pathogenic variants of TNNC1 have been associated with DCM and HCM in OMIM and 423 many reported variants in this gene support this association (Parvatiyar et al., 2012; Pinto et al., 424 2011). Although HCM is typically inherited in an autosomal dominant manner, the presence of  $425$  homozygous situation in our study, with another mutation in the same gene, causing RCM in a 426 case study presented by Ploski et al., suggests that pathogenic variants in this gene may have an 427 autosomal recessive inheritance pattern for RCM (Ploski et al., 2016). Also, the variability of 428 Ca2+ concentration, which affects myofilament function for each subtype, can create a 429 difference for the expressional variability of cardiomyopathy. For example, high Ca2+ levels 430 during contraction have been associated with hypertrophy in heart muscle, while low levels 431 have been associated with dilation. Hence, the importance of investigating the role of 432 mitochondria, which play a significant role in the storage of cytosolic Ca2+, in terms of the full 433 diagnosis, progression, and treatment of the disease has been approved (Willott et al., 2010).

434 As stated by the ACMG, interpreting mitochondrial variants is complex and challenging 435 (Richards et al., 2015). Due to the unique characteristics of mitochondrial inheritance, such as 436 heteroplasmy and homoplasmy and specific geographic regions, certain tools should be 437 developed to specifically analyze mtDNA variants. In addition to rare cases, mtDNA, which is 438 transmitted through the maternal line and is different from Mendelian inheritance, plays an 439 important role in the evolutionary process of humans and diseases (Wallace, 2015). 440 Haplogroups, have been the subject of many recent studies, particularly in the context of 441 neurodegenerative diseases and regional/geographic predispositions to certain disorders 442 (Chinnery & Gomez-Duran, 2018; Wallace, 2018). In this study, we investigated possible genetic 443 explanations of pediatric cardiomyopathies by analyzing both nuclear DNA and mitochondrial

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

444 DNA. Our study is also the first high-throughput sequencing study of mtDNA in Central Region 445 of Anatolia Peninsula (Turkey) that aims to contribute to the country's mtDNA haplogroup map 446 by interpreting ethnic/regional haplogroup variations. Since it is discussed that genetic 447 predispositions to diseases can be geographically determined(Yusuf et al., 2001), this study 448 conducted in our region presents a promising analysis for promising targeted mitochondrial 449 therapies developed recently(Nissanka & Moraes, 2020). Even though the sample size is not 450 diverse enough to generalize the findings to the larger non-syndromic or isolated pediatric 451 cardiomyopathy population and the study only examined a limited number of genes, this 452 combined analysis could provide insights into the etiology of certain idiopathic cardiovascular 453 diseases.

454 In addition, considering the large size of TTN and many variants found in this gene, it can 455 be argued that some functional studies should concentrate only on TTN. Furthermore, in this 456 study, we identified 10 novel variants in four genes that could potentially be directly related to 457 cardiomyopathy and two genes that could be indirectly related. Pediatric manifestations with 458 their genetic analyses included in this study will be useful for pediatricians to support the use of 459 genetic testing and for researchers to investigate new genetic factors. In addition, it is essential 460 to evaluate mtDNA variants together with nuclear DNA variants, especially in tissues where 461 bioenergetic pathways are actively involved in the pathology.

#### 462 MATERIALS AND METHODS

#### 463 Ethical approval

464 This study was conducted according to the guidelines of the Declaration of Helsinki and 465 approved by the clinical practice ethics committee of a hospital. Informed consent was 466 obtained from the parents or legal guardians of the probands, and each participant provided 467 informed consent. We also followed STROBE guidelines for reporting observational studies(von 468 Elm et al., 2007).

469 Diagnosis

470 All 27 patients were evaluated in pediatric cardiology department between 2018-2020. 471 Transthoracic echocardiogram (TTE) and a 12-lead electrocardiogram (ECG) was used as initial 472 modalities and, 24- to 48-hour ambulatory electrocardiographic monitoring, exercise TTE,

It is made available under a CC-BY-NC-ND 4.0 International license.

473 intraoperative transesophageal echocardiogram (TEE), cardiac magnetic resonance imaging 474 (MRI) was used when necessary.

475 Children with positive family history and left ventricular wall thickness more than 2 476 standard deviations (SD) from the predicted mean and without family history, more than 2.5 477 SDs were diagnosed with hypertrophic cardiomyopathy (HCM) according to 2020 AHA/ACC 478 guidelines(null et al., 2020). Children with reduced left ventricular ejection fraction (LVEF) 479 (<50%) with enlarged left ventricle volume in the absence of other cardiac findings including 480 coronary artery disease, primary valvular heart disease in addition other systemic and extrinsic 481 reasons including hypothyroidism, toxins and medications were diagnosed with dilated 482 cardiomyopathy (DCM)(Libby et al., 2021). There were only two having restricted 483 cardiomyopathy (RCM) who were children of first-degree cousins. They had reduced ventricular 484 filling with normal/near normal ejection fraction and myocardial thickness and mildly reduced 485 diastolic volumes. These patients were diagnosed with restrictive cardiomyopathy (RCM) in the 486 presence of all these findings according to ESC(Elliott et al., 2007). The left ventricular non-487 compaction (LVNC) group was diagnosed according to morphological diagnostic criteria stated 488 by Jenni et al; multiple trabeculations in echocardiographic imagining, multiple communicating 489 ventricular cavities and intertrabecular recesses in color Doppler imaging, recesses within the 490 middle and apical side of the ventricle, and a noncompacted to compacted ratio more than 1.4, 491 in addition to the endocardium with two layered constructions(Jenni et al., 2001).

492 The subjects were then elaboratively evaluated by clinical geneticists to exclude 493 secondary causes of cardiomyopathy, including RASopathies, muscular dystrophies, Barth 494 syndrome and other metabolic disorders. They were evaluated for neurodevelopmental 495 milestones, intellectual capability, and underwent a systemic examination with anthropometric 496 measurements, dysmorphic feature inspection, organomegaly examination, and neurological 497 examination. Perinatal history and pedigree analysis were also assessed, and ophthalmological 498 and auditory examinations were done if needed. Initially, there were 32 participants, but one of 499 them voluntarily withdrew from the study, resulting in a total of 31 participants for the control 500 group. They had no history of heart problems or familial heart and syndromic findings, as 501 confirmed by cardiology and genetics clinic.

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

#### 502 Demographic features

503 There are a total of 27 patients 12 of whom were female and 15 were male. The mean 504 diagnose age ranged from 0.54 for RCM, 1.41 for DCM to 8.6 for LVNC, with HCM having the 505 second highest mean diagnose age of 8.42 years. The control group included 31 individuals, 21 506 of whom were female and 10 were male, with a mean age of 10.03 years. The figure (Figure 2A) 507 summarizes this feature across phenotypes. Detailed demographic and clinical summary of the 508 study participants can be found in Supplementary Table S1A.

#### 509 Sample collection and DNA isolation

510 Approximately 400 µl of peripheral whole-blood samples from 58 individuals were 511 collected into EDTA containing tubes. MagPurix robotic system and its isolation kit were used in 512 accordance with the manufacturer's instructions. Around 100 µl of total genomic DNA was 513 isolated at a concentration range of 30-100 ng/µl measured by NanoDrop and these samples 514 were stored at -20°C.

#### 515 Sequencing and bioinformatic analyses

516 Library was prepared according to Illumina Trusight Enrichment and clinical exome 517 sequencing was performed in Illumina-NextSeq500 platform. Mitochondrial DNA was 518 subsequently sequenced on IonTorrent-S5 platform. The library preparation was conducted 519 using the Ion AmpliSeq™ Library Kit 2.0 and Precision-ID mtDNA Whole Genome Panel by 520 following the manufacturer's guide. Sequenced output data (fastq files) were aligned to the 521 related genes of human reference genome (UCSC hg19/GRCh37) by BWA-mem (v.0.7.12) (H. Li, 522 2013) and quality assessments were performed by using FastQC(S. Andrews, 2010). After 523 quality trimming and filtering the bad reads out, variant calling was performed by GATK 524 (v.4.0)(A. McKenna et al., 2010). For mtDNA variant calling mtDNA\_rCRS (NC\_012920.1) is used 525 as a reference genome for alignment(R. M. Andrews et al., 1999) and Torrent Variant Caller 526 plugin v.5.2.1.39 was used for variant calling. Confirmation of meaningful variants using Sanger 527 sequencing has not yet been carried out except novel mtDNA variant (m.684T>C).

528 All variants identified in 137 genes that are associated cardiomyopathy and in mtDNA 529 were obtained in VCF format then filtered according to following criteria: 1) Variants at the 530 exonic regions with AF<0.01 and read depth of at least 20x were included. 2) mtDNA variants

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

531 were compared to the control group variants, and if they were found in the control group, they 532 were not considered for evaluation.

533 General data handling was performed with and "R" base functions and (version 4.2.1, [R 534 Core Team 2022]), and R packages; ggplot2 and dplyr for plotting(*Dplyr: A Grammar of Data*<br>535 *Manipulation,* 2021; Wickham, 2016). After filters were established for nDNA variants, *in silico* 535 *Manipulation,* 2021; Wickham, 2016). After filters were established for nDNA variants, *in silico*<br>536 evaluations of the variants were carried out using VEP through different prediction tools and 536 evaluations of the variants were carried out using VEP through different prediction tools and 537 PHACT, which was recently developed(Kuru et al., 2022; McLaren et al., 2016). For mtDNA 538 variants, 'bam' files were converted to 'fasta' files through MitoSuite, which would give the 539 consensus sequence of the reading. Variant analyses were performed on these 'fasta' files 540 through Mitomap-MITOMASTER(Lott et al., 2013). Additionally, these variants identified in the 541 patient group were also investigated *in silico* through PolyPhen2-HumDiv and HumVar,<br>542 MSeqDR, and HmtVar(Preste et al., 2019; Shen et al., 2018). Population data and conservation 542 MSeqDR, and HmtVar(Preste et al., 2019; Shen et al., 2018). Population data and conservation 543 scores were obtained through Mitomap. For the mtDNA-phylogenetic tree, variants were 544 evaluated and haplogroups were retrieved from Haplogrep (v.2) using 545 PhyloTree17(Weissensteiner et al., 2016). Chi-squared tests were performed using stats 546 package of R to compare the distribution of distinct haplogroups between patient and control 547 groups and p<0.05 was determined as significant. The mitochondrial solar plot shown in the 548 figure was adapted from Stephen Turner's github account(S*tephenturner/Solarplot:*<br>549 *Mitochondrial Solar Plot*.n.d.). 549 Mitochondrial Solar Plot, n.d.).<br>550 **Data availability** 

#### Data availability

551 Sequencing data for cardiomyopathy-associated genes in VCF file except five patients 552 who are not alive will be shared reasonable request to corresponding author. Moreover, 553 aligned mtDNA-seq data for 27 patients and 31 individuals in control group are publicly 554 available upon publication on Sequence Read Archive (SRA) under BioProject Number 555 PRJNA1028644 on NCBI. Notably, unfiltered variants for both mtDNA and nDNA are provided in 556 Supplementary Table S1B, Table S1C, and Table S1D along with the information of 137 genes.

#### 557 ACKNOWLEDGEMENTS & FUNDING

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

558 The designed study has been supported by scientific grant programs within the 559 university under the supervision of Dr. Ebru Erzurumluoglu Gökalp to support Mehmet Arda 560 Temena's master thesis.

# 561 FIGURE LEGENDS

Figure 1. Genetic profiling in pediatric cardiomyopathies.

- 563 Figure 2. General demographic features of the patients and the study highlights.
- 564 Figure 3. Solar Plot of Mitochondrial Variants in Cardiomyopathy Subtypes.
- 565 Figure 4. Overall identified and filtered mtDNA Variants and Pedigree analysis of the 566 patients.

### 567 SUPPLEMENTARY FILES

568 Supplementary Figures

- 569 **Supplementary Figure S1.** Summary of nDNA Variants Grouped by Genes and 570 Genotypes.
- 571 **Supplementary Figure S2.** Summary of VUS and Pathogenic nDNA Variants Grouped by

572 Genes, Genotypes, and Cardiomyopathy Subtypes

- 573 Supplementary Figure S3. All mtDNA Variants Identified in Patients.
- 574 Supplementary Figure S4. All mtDNA Variants Identified in Control Group.
- 575 Supplementary Figure S5. Filtered mtDNA Variants Grouped by Genes, Genotypes, and
- 576 Cardiomyopathy Subtypes
- 577 **Supplementary Table S1.** Detailed information of patients and all 137 nDNA genes and 578 variants
- 579 Supplementary Table S2. Detailed haplogroup information and mtDNA variants.

#### 580 CONFLICT OF INTEREST

581 Authors declare no conflict of interest.

# 582 **AUTHOR CONTRIBUTIONS**<br>583 MAT and EEG conceptualized are

MAT and EEG conceptualized and designed the project. Funding acquisition was done by 584 EEG and OC. MAT and DC performed all wet-lab procedures. MAT performed bioinformatics 585 analyses and visualized the data. MAT, EEG and ES interpreted the results. PG and HK were

It is made available under a CC-BY-NC-ND 4.0 International license.

- 586 involved in diagnosing the patients. MAT, EEG, and ES provided discussion. BDA, SA and OC
- 587 supervised the project. MAT wrote the manuscript with final approval of all authors.

#### 588 REFERENCES

- 589 Alamo, L., Ware, J. S., Pinto, A., Gillilan, R. E., Seidman, J. G., Seidman, C. E., & Padron, R. (2017). 590 Effects of myosin variants on interacting-heads motif explain distinct hypertrophic and
- 
- dilated cardiomyopathy phenotypes. *Elife, 6,* e24634.<br>592 Andrews, R. M., Kubacka, I., Chinnery, P. F., Lightowlers, R.<br>593 (1999). Reanalysis and revision of the Cambridge refer 592 Andrews, R. M., Kubacka, I., Chinnery, P. F., Lightowlers, R. N., Turnbull, D. M., & Howell, N.
- 593 (1999). Reanalysis and revision of the Cambridge reference sequence for human
- mitochondrial DNA. *Nature Genetics, 23*(2), 147.<br>595 Andrews, S. (2010). *FastQC: a quality control tool for h*<br>596 Bioinformatics, Babraham Institute, Cambridge, l 595 Andrews, S. (2010). *FastQC: a quality control tool for high throughput sequence data*. Babraham<br>596 Bioinformatics, Babraham Institute, Cambridge, United Kingdom.<br>597 Anna, G., Bärbel, K., 596 Bioinformatics, Babraham Institute, Cambridge, United Kingdom.
- 597 Anna, G., Bärbel, K., Andreas, B., & Hendrik, M. (2020). RBM20 mutations in left ventricular 598 non-compaction cardiomyopathy. Pediatric Investigation, 04(01), 61–63. 600 Arbustini, E., Narula, N., Tavazzi, L., Serio, A., Grasso, M., Favalli, V., Bellazzi, R., Tajik, J. A., 599 https://doi.org/10.1002/ped4.12184
- 601 Bonow, R. O., Fuster, V., & Narula, J. (2014). The MOGE(S) Classification of
- 602 Cardiomyopathy for Clinicians. Journal of the American College of Cardiology, 64(3), 304– 604 Bagnall, R. D., Singer, E. S., Wacker, J., Nowak, N., Ingles, J., King, I., Macciocca, I., Crowe, J., 603 318. https://doi.org/https://doi.org/10.1016/j.jacc.2014.05.027
- 605 Ronan, A., Weintraub, R. G., & Semsarian, C. (2022). Genetic Basis of Childhood 606 Cardiomyopathy. Circulation: Genomic and Precision Medicine, 15(6), e003686. 608 Bottillo, I., D'Angelantonio, D., Caputo, V., Paiardini, A., Lipari, M., De Bernardo, C., Giannarelli, 607 https://doi.org/10.1161/CIRCGEN.121.003686
- 
- 609 D., Pizzuti, A., Majore, S., Castori, M., Zachara, E., Re, F., & Grammatico, P. (2016).
- 610 Molecular analysis of sarcomeric and non-sarcomeric genes in patients with hypertrophic 611 cardiomyopathy. Gene, 577(2), 227–235. 613 Chinnery, P. F., & Gomez-Duran, A. (2018). Oldies but Goldies mtDNA Population Variants and
- 612 https://doi.org/https://doi.org/10.1016/j.gene.2015.11.048
- 614 Neurodegenerative Diseases . In Frontiers in Neuroscience (Vol. 12, p. 682). 616 Dorn, G. W. (2015). Mitochondrial dynamism and heart disease: changing shape and shaping
- 615 https://www.frontiersin.org/article/10.3389/fnins.2018.00682
- 617 change. *EMBO Molecular Medicine, 7*(7), 865-877–877.<br>618 https://doi.org/https://doi.org/10.15252/emmm.2014C<br>619 dplyr: A Grammar of Data Manipulation (1.0.7). (2021). https
- 618 https://doi.org/https://doi.org/10.15252/emmm.201404575
- 
- 620 project.org/package=dplyr
- 619 *dplyr: A Grammar of Data Manipulation* (1.0.7). (2021). https://cran.r-<br>620 project.org/package=dplyr<br>621 Elliott, P., Andersson, B., Arbustini, E., Bilinska, Z., Cecchi, F., Charron, I 621 Elliott, P., Andersson, B., Arbustini, E., Bilinska, Z., Cecchi, F., Charron, P., Dubourg, O., Kühl, U., 622 Maisch, B., McKenna, W. J., Monserrat, L., Pankuweit, S., Rapezzi, C., Seferovic, P., Tavazzi, 623 L., & Keren, A. (2007). Classification of the cardiomyopathies: a position statement from 624 the european society of cardiology working group on myocardial and pericardial diseases.
- 
- 625 European Heart Journal, 29(2), 270–276. https://doi.org/10.1093/eurheartj/ehm342<br>626 Elson, J. L., Smith, P. M., Greaves, L. C., Lightowlers, R. N., Chrzanowska-Lightowlers, Z. M.<br>627 Taylor, R. W., & Vila-Sanjurjo, A. 626 Elson, J. L., Smith, P. M., Greaves, L. C., Lightowlers, R. N., Chrzanowska-Lightowlers, Z. M. A.,
	- Taylor, R. W., & Vila-Sanjurjo, A. (2015). The presence of highly disruptive 16S rRNA

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

628 mutations in clinical samples indicates a wider role for mutations of the mitochondrial 629 ribosome in human disease. Mitochondrion, 25, 17–27. 631 Fernandez-Vizarra, E., & Zeviani, M. (2021). Mitochondrial disorders of the OXPHOS system. 630 https://doi.org/https://doi.org/10.1016/j.mito.2015.08.004 632 FEBS Letters, 595(8), 1062–1106. https://doi.org/https://doi.org/10.1002/1873-<br>633 3468.13995<br>634 Fiorillo, C., Astrea, G., Savarese, M., Cassandrini, D., Brisca, G., Trucco, F., Pedemonte<br>635 Trovato, R., Ruggiero, L. 633 3468.13995 634 Fiorillo, C., Astrea, G., Savarese, M., Cassandrini, D., Brisca, G., Trucco, F., Pedemonte, M., Trovato, R., Ruggiero, L., Vercelli, L., D'Amico, A., Tasca, G., Pane, M., Fanin, M., Bello, L., 636 Broda, P., Musumeci, O., Rodolico, C., Messina, S., … Bruno, C. (2016). MYH7-related 637 myopathies: Clinical, histopathological and imaging findings in a cohort of Italian patients. 638 Orphanet Journal of Rare Diseases. https://doi.org/10.1186/s13023-016-0476-1<br>639 Gaertner, A., Bloebaum, J., Brodehl, A., Klauke, B., Sielemann, K., Kassner, A., Fox, H.,<br>640 M., Tiesmeier, J., & Schulz, U. (2021). The 639 Gaertner, A., Bloebaum, J., Brodehl, A., Klauke, B., Sielemann, K., Kassner, A., Fox, H., Morshuis, 640 M., Tiesmeier, J., & Schulz, U. (2021). The combined human genotype of truncating TTN 641 and RBM20 mutations is associated with severe and early onset of dilated 642 cardiomyopathy. *Genes, 12*(6), 883.<br>643 Geske, J. B., Ommen, S. R., & Gersh, B. J.<br>644 *JACC: Heart Failure, 6*(5), 364–375. 643 Geske, J. B., Ommen, S. R., & Gersh, B. J. (2018). Hypertrophic Cardiomyopathy: Clinical Update. 644 JACC: Heart Failure, 6(5), 364–375. 646 Guo, H., Liu, L., Nishiga, M., Cong, L., & Wu, J. C. (2021). Deciphering pathogenicity of variants of 645 https://doi.org/https://doi.org/10.1016/j.jchf.2018.02.010 uncertain significance with CRISPR-edited iPSCs. Trends in Genetics, 37(12), 1109–1123.<br>648 https://doi.org/10.1016/j.tig.2021.08.009<br>649 Guo, W., Schafer, S., Greaser, M. L., Radke, M. H., Liss, M., Govindarajan, T., Maat 648 https://doi.org/10.1016/j.tig.2021.08.009 649 Guo, W., Schafer, S., Greaser, M. L., Radke, M. H., Liss, M., Govindarajan, T., Maatz, H., Schulz, 650 H., Li, S., Parrish, A. M., Dauksaite, V., Vakeel, P., Klaassen, S., Gerull, B., Thierfelder, L., 651 Regitz-Zagrosek, V., Hacker, T. A., Saupe, K. W., Dec, G. W., … Gotthardt, M. (2012). 652 RBM20, a gene for hereditary cardiomyopathy, regulates titin splicing. *Nature Medicine*,<br>653 18(5), 766–773. https://doi.org/10.1038/nm.2693<br>654 Gutell, R. R., Lee, J. C., & Cannone, J. J. (2002). The accuracy of ribo 653 18(5), 766–773. https://doi.org/10.1038/nm.2693 654 Gutell, R. R., Lee, J. C., & Cannone, J. J. (2002). The accuracy of ribosomal RNA comparative 655 structure models. Current Opinion in Structural Biology, 12(3), 301–310. 657 Herman, D. S., Lam, L., Taylor, M. R. G., Wang, L., Teekakirikul, P., Christodoulou, D., Conner, L., 656 https://doi.org/https://doi.org/10.1016/S0959-440X(02)00339-1 658 DePalma, S. R., McDonough, B., Sparks, E., Teodorescu, D. L., Cirino, A. L., Banner, N. R., 659 Pennell, D. J., Graw, S., Merlo, M., Di Lenarda, A., Sinagra, G., Bos, J. M., … Seidman, C. E. 660 (2012). Truncations of Titin Causing Dilated Cardiomyopathy. *New England Journal of*<br>661 Medicine, 366(7), 619–628. https://doi.org/10.1056/NEJMoa1110186<br>662 Hershberger, R. E., Hedges, D. J., & Morales, A. (2013). Di Medicine, 366(7), 619–628. https://doi.org/10.1056/NEJMoa1110186<br>662 Hershberger, R. E., Hedges, D. J., & Morales, A. (2013). Dilated cardiomyopa<br>663 of a diverse genetic architecture. *Nature Revie* 662 Hershberger, R. E., Hedges, D. J., & Morales, A. (2013). Dilated cardiomyopathy: the complexity 663 of a diverse genetic architecture. *Nature Reviews Cardiology, 10*(9), 531–547.<br>664 https://doi.org/10.1038/nrcardio.2013.105<br>665 Hershberger, R. E., & Jordan, E. (2022). Dilated cardiomyopathy overview. 664 https://doi.org/10.1038/nrcardio.2013.105 666 Genereviews®[Internet]. 667 Hershberger, R. E., Morales, A., & Cowan, J. (2017). Is left ventricular noncompaction a trait, 668 phenotype, or disease? The evidence points to phenotype. In *Circulation: Cardiovascular*<br>669 *Genetics* (Vol. 10, Issue 6, p. e001968). Am Heart Assoc.<br>670 Huigsloot, M., Nijtmans, L. G., Szklarczyk, R., Baars, M. J. 669 *Genetics* (Vol. 10, Issue 6, p. e001968). Am Heart Assoc.<br>670 Huigsloot, M., Nijtmans, L. G., Szklarczyk, R., Baars, M. J. H., van den Brand, M. A. M.,<br>671 HendriksFranssen, M. G. 670 Huigsloot, M., Nijtmans, L. G., Szklarczyk, R., Baars, M. J. H., van den Brand, M. A. M.,



It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .



It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .



It is made available under a CC-BY-NC-ND 4.0 International license.

802 variants in JPH2-encoded junctophilin-2. Trends in Cardiovascular Medicine, 33(1), 1–10. 804 Parvatiyar, M. S., Landstrom, A. P., Figueiredo-Freitas, C., Potter, J. D., Ackerman, M. J., & Pinto, 803 https://doi.org/https://doi.org/10.1016/j.tcm.2021.11.006 805 J. R. (2012). A mutation in TNNC1-encoded cardiac troponin C, TNNC1-A31S, predisposes 806 to hypertrophic cardiomyopathy and ventricular fibrillation. *The Journal of Biological*<br>807 *Chemistry, 287*(38), 31845–31855. https://doi.org/10.1074/jbc.M112.377713<br>808 Pinto, J. R., 807 Chemistry, 287(38), 31845–31855. https://doi.org/10.1074/jbc.M112.377713 809 D., & Hershberger, R. E. (2011). Functional characterization of TNNC1 rare variants 810 identified in dilated cardiomyopathy. The Journal of Biological Chemistry, 286(39), 34404– 812 Ploski, R., Rydzanicz, M., Ksiazczyk, T. M., Franaszczyk, M., Pollak, A., Kosinska, J., Michalak, E., 811 34412. https://doi.org/10.1074/jbc.M111.267211 813 Stawinski, P., Ziolkowska, L., Bilinska, Z. T., & Werner, B. (2016). Evidence for troponin C 814 (TNNC1) as a gene for autosomal recessive restrictive cardiomyopathy with fatal outcome 815 in infancy. American Journal of Medical Genetics Part A, 170(12), 3241–3248. 817 Preste, R., Vitale, O., Clima, R., Gasparre, G., & Attimonelli, M. (2019). HmtVar: a new resource 816 https://doi.org/10.1002/ajmg.a.37860 818 for human mitochondrial variations and pathogenicity data. *Nucleic Acids Research,*<br>819 47(D1), D1202–D1210.<br>820 Rath, S., Sharma, R., Gupta, R., Ast, T., Chan, C., Durham, T. J., Goodman, R. P., Grabarek, 819 47(D1), D1202–D1210. 820 Rath, S., Sharma, R., Gupta, R., Ast, T., Chan, C., Durham, T. J., Goodman, R. P., Grabarek, Z., 821 Haas, M. E., Hung, W. H. W., Joshi, P. R., Jourdain, A. A., Kim, S. H., Kotrys, A. V, Lam, S. S., 822 McCoy, J. G., Meisel, J. D., Miranda, M., Panda, A., … Mootha, V. K. (2021). MitoCarta3.0: 823 an updated mitochondrial proteome now with sub-organelle localization and pathway annotations. *Nucleic Acids Research, 49*(D1), D1541–D1547.<br>825 https://doi.org/10.1093/nar/gkaa1011<br>826 Rebs, S. (2021). *Analysis of splice-defect associated cardiac diseases using a patient-specific*<br>827 *iPSC-cardiomyo* 825 https://doi.org/10.1093/nar/gkaa1011 826 Rebs, S. (2021). *Analysis of splice-defect associated cardiac diseases using a patient-specific*<br>827 *iPSC-cardiomyocyte system.* https://ediss.uni-goettingen.de/handle/21.11130/00-1735<br>828 827 iPSC-cardiomyocyte system. https://ediss.uni-goettingen.de/handle/21.11130/00-1735- 828 0000-0005-154B-0 829 Richards, S., Aziz, N., Bale, S., Bick, D., Das, S., Gastier-Foster, J., Grody, W. W., Hegde, M., Lyon, 830 E., Spector, E., Voelkerding, K., Rehm, H. L., & Committee, A. L. Q. A. (2015). Standards and 831 guidelines for the interpretation of sequence variants: a joint consensus recommendation 832 of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. *Genetics in Medicine*L: *Official Journal of the American College of*<br>834 Medical Genetics, 17(5), 405–424. https://doi.org/10.1038/gim.2015.30<br>835 Riemersma, M., Hazebroek, M. R., Helderman-van den E 834 Medical Genetics, 17(5), 405–424. https://doi.org/10.1038/gim.2015.30<br>835 Riemersma, M., Hazebroek, M. R., Helderman-van den Enden, A. T. J. M., Salomons, G. S.,<br>836 Ferdinandusse 835 Riemersma, M., Hazebroek, M. R., Helderman-van den Enden, A. T. J. M., Salomons, G. S., 837 den Wijngaard, A., Krapels, I. P. C., Bierau, J., & Brunner, H. G. (2017). Propionic acidemia 838 as a cause of adult-onset dilated cardiomyopathy. European Journal of Human Genetics, 839 25(11), 1195–1201. https://doi.org/10.1038/ejhg.2017.127 840 Ripoll-Vera, T., Gámez, J. M., Govea, N., Gómez, Y., Núñez, J., Socías, L., Escandell, Á., & Rosell, J. 841 (2016). Clinical and Prognostic Profiles of Cardiomyopathies Caused by Mutations in the 842 Troponin T Gene. Revista Espanola de Cardiologia (English Ed.), 69(2), 149–158. 843 https://doi.org/10.1016/j.rec.2015.06.025 844 Roberts, A. M., Ware, J. S., Herman, D. S., Schafer, S., Baksi, J., Bick, A. G., Buchan, R. J., Walsh, 845 R., John, S., Wilkinson, S., Mazzarotto, F., Felkin, L. E., Gong, S., L. MacArthur, J. A.,

846 Cunningham, F., Flannick, J., Gabriel, S. B., Altshuler, D. M., Macdonald, P. S., … Cook, S. A. 847 (2015). Integrated allelic, transcriptional, and phenomic dissection of the cardiac effects of 848 titin truncations in health and disease. Science Translational Medicine, 7(270), 270ra6- 850 Sabater-Molina, M., Navarro, M., García-Molina Sáez, E., Garrido, I., Pascual-Figal, D., González 849 270ra6. https://doi.org/10.1126/scitranslmed.3010134 851 Carrillo, J., & Gimeno Blanes, J. R. (2016). Mutation in JPH2 cause dilated cardiomyopathy. 852 Clinical Genetics, 90(5), 468–469. https://doi.org/https://doi.org/10.1111/cge.12825<br>853 Sanganalmath, S. K., & Bolli, R. (2013). Cell Therapy for Heart Failure. *Circulation Research,*<br>854 113(6), 810–834. https://doi 853 Sanganalmath, S. K., & Bolli, R. (2013). Cell Therapy for Heart Failure. *Circulation Research,*<br>854 *113*(6), 810–834. https://doi.org/10.1161/CIRCRESAHA.113.300219<br>855 Santorelli, F. M., T 854 113(6), 810–834. https://doi.org/10.1161/CIRCRESAHA.113.300219 855 Santorelli, F. M., Tanji, K., Manta, P., Casali, C., Krishna, S., Hays, A. P., Mancini, D. M., DiMauro, 856 S., & Hirano, M. (1999). Maternally Inherited Cardiomyopathy: An Atypical Presentation of 857 the mtDNA 12S rRNA Gene A1555G Mutation. *The American Journal of Human Genetics,*<br>858 *64*(1), 295–300. https://doi.org/10.1086/302188<br>859 Sedaghat-Hamedani, F., Haas, J., Zhu, F., Ge 858 64(1), 295–300. https://doi.org/10.1086/302188 859 Sedaghat-Hamedani, F., Haas, J., Zhu, F., Geier, C., Kayvanpour, E., Liss, M., Lai, A., Frese, K., 860 Pribe-Wolferts, R., Amr, A., Li, D. T., Samani, O. S., Carstensen, A., Bordalo, D. M., Müller, 861 M., Fischer, C., Shao, J., Wang, J., Nie, M., … Meder, B. (2017). Clinical genetics and outcome of left ventricular non-compaction cardiomyopathy. *European Heart Journal,*<br>863 38(46), 3449–3460. https://doi.org/10.1093/eurheartj/ehx545<br>864 Sedaghat-Hamedani, F., Haas, J., Zhu, F., Kayvanpour, E., Geier, C., 863 38(46), 3449–3460. https://doi.org/10.1093/eurheartj/ehx545 865 Liss, M., Ehlermann, P. H., Dieterich, C., Gotthardt, M., Katus, H. A., & Meder, B. (2017). 864 Sedaghat-Hamedani, F., Haas, J., Zhu, F., Kayvanpour, E., Geier, C., Lai, A., Frese, K., Amr, A., 866 P1338Mutations in RBM20 and titin cause left ventricular non-compaction 867 cardiomyopathy. European Heart Journal, 38(suppl\_1), ehx502.P1338. 869 Shen, L., Attimonelli, M., Bai, R., Lott, M. T., Wallace, D. C., Falk, M. J., & Gai, X. (2018). MSeqDR 868 https://doi.org/10.1093/eurheartj/ehx502.P1338 870 mvTool: A mitochondrial DNA Web and API resource for comprehensive variant annotation, universal nomenclature collation, and reference genome conversion. Human<br>872 Mutation, 39(6), 806–810. https://doi.org/10.1002/humu.23422<br>873 Smeitink, J. A. M., Elpeleg, O., Antonicka, H., Diepstra, H., Saada, 872 Mutation, 39(6), 806–810. https://doi.org/10.1002/humu.23422 874 Vriend, G., Jacob-Hirsch, J., & Shaag, A. (2006). Distinct clinical phenotypes associated with 873 Smeitink, J. A. M., Elpeleg, O., Antonicka, H., Diepstra, H., Saada, A., Smits, P., Sasarman, F., It is made available under a CC-BY-NC-ND 4.0 International license.

- 875 a mutation in the mitochondrial translation elongation factor EFTs. The American Journal
- 876 *of Human Genetics, 79*(5), 869–877.<br>877 Smith, P. M., Elson, J. L., Greaves, L. C., W<br>878 Chrzanowska-Lightowlers, Z. M. A., T 877 Smith, P. M., Elson, J. L., Greaves, L. C., Wortmann, S. B., Rodenburg, R. J. T., Lightowlers, R. N., 878 Chrzanowska-Lightowlers, Z. M. A., Taylor, R. W., & Vila-Sanjurjo, A. (2013). The role of the 879 mitochondrial ribosome in human disease: searching for mutations in 12S mitochondrial
- 881 https://doi.org/10.1093/hmg/ddt490
- 880 rRNA with high disruptive potential. Human Molecular Genetics, 23(4), 949–967. 882 s*tephenturner/solarplot: Mitochondrial Solar Plot*. (n.d.). Retrieved 24 October 2023, from<br>883 https://github.com/stephenturner/solarplot<br>884 Sun, Q., Guo, J., Hao, C., Guo, R., Hu, X., Chen, Y., 883 https://github.com/stephenturner/solarplot
- 884 Sun, Q., Guo, J., Hao, C., Guo, R., Hu, X., Chen, Y., Yang, W., Li, W., & Feng, Y. (2020). 885 Whole-exome sequencing reveals two de novo variants in the RBM20 gene in two Chinese
- 886 patients with left ventricular non-compaction cardiomyopathy. *Pediatric Investigation,*<br>1987 A. (1), 11–16.<br>1988 Tahrir, F. G., Knezevic, T., Gupta, M. K., Gordon, J., Cheung, J. Y., Feldman, A. M., & Khalili, K 887 4(1), 11–16.
- 888 Tahrir, F. G., Knezevic, T., Gupta, M. K., Gordon, J., Cheung, J. Y., Feldman, A. M., & Khalili, K.
- 889 (2017). Evidence for the Role of BAG3 in Mitochondrial Quality Control in Cardiomyocytes.

It is made available under a CC-BY-NC-ND 4.0 International license.

890 *Journal of Cellular Physiology, 232*(4), 797–805.<br>891 https://doi.org/https://doi.org/10.1002/jcp.254<br>892 Takeda, A. (2020). Mitochondrial cardiomyopathy. *J F* 891 https://doi.org/https://doi.org/10.1002/jcp.25476 892 Takeda, A. (2020). Mitochondrial cardiomyopathy. *J Pediatr Cardiol Card Surg, 4,* 53–62.<br>893 Tang, S., Batra, A., Zhang, Y., Ebenroth, E. S., & Huang, T. (2010). Left ventricular<br>894 nonc 893 Tang, S., Batra, A., Zhang, Y., Ebenroth, E. S., & Huang, T. (2010). Left ventricular 894 noncompaction is associated with mutations in the mitochondrial genome. *Mitochondrion*,<br>895 10(4), 350–357. https://doi.org/https://doi.org/10.1016/j.mito.2010.02.003<br>896 Tashiro, R. (2018). *Mitochondrial Cardiomyopa* 896 1Tashiro, R. (2018). *Mitochondrial Cardiomyopathy* (N. Onoue, Ed.; p. Ch. 1). IntechOpen.<br>197 https://doi.org/10.5772/intechopen.77105<br>198 Tobita, T., Nomura, S., Fujita, T., Morita, H., Asano, Y., Onoue, K., Ito, M., 896 Tashiro, R. (2018). *Mitochondrial Cardiomyopathy* (N. Onoue, Ed.; p. Ch. 1). IntechOpen.<br>897 https://doi.org/10.5772/intechopen.77105<br>898 Tobita, T., Nomura, S., Fujita, T., Morita, H., Asa 897 https://doi.org/10.5772/intechopen.77105 899 T., Satoh, M., Fujita, K., Naito, A. T., Furutani, Y., Toko, H., Harada, M., Amiya, E., Hatano, 900 M., Takimoto, E., … Komuro, I. (2018). Genetic basis of cardiomyopathy and the genotypes 901 involved in prognosis and left ventricular reverse remodeling. *Scientific Reports, 8*(1), 1998.<br>902 https://doi.org/10.1038/s41598-018-20114-9<br>903 Toepfer, C. N., Garfinkel, A. C., 902 https://doi.org/10.1038/s41598-018-20114-9 904 Agarwal, R., Ewoldt, J. F., & Cloonan, P. (2020). Myosin sequestration regulates sarcomere 905 function, cardiomyocyte energetics, and metabolism, informing the pathogenesis of 906 hypertrophic cardiomyopathy. *Circulation, 141*(10), 828–842.<br>907 van Waning, J. I., Caliskan, K., Hoedemaekers, Y. M., van Spaendon<br>908 Boekholdt, S. M., van Melle, J. P., Teske, A. J., Asselberg 907 van Waning, J. I., Caliskan, K., Hoedemaekers, Y. M., van Spaendonck-Zwarts, K. Y., Baas, A. F., 908 Boekholdt, S. M., van Melle, J. P., Teske, A. J., Asselbergs, F. W., & Backx, A. P. C. M. (2018). 909 Genetics, clinical features, and long-term outcome of noncompaction cardiomyopathy. 910 *Journal of the American College of Cardiology, 71*(7), 711–722.<br>911 Velicki, L., Jakovljevic, D. G., Preveden, A., Golubovic, M., Bjelobrk, N<br>912 Barlocco, F., Tafelmeier, M., Okwose 911 Velicki, L., Jakovljevic, D. G., Preveden, A., Golubovic, M., Bjelobrk, M., Ilic, A., Stojsic, S., 912 Barlocco, F., Tafelmeier, M., Okwose, N., Tesic, M., Brennan, P., Popovic, D., Ristic, A., 913 MacGowan, G. A., Filipovic, N., Maier, L. S., & Olivotto, I. (2020). Genetic determinants of clinical phenotype in hypertrophic cardiomyopathy. *BMC Cardiovascular Disorders, 20*(1),<br>915 516. https://doi.org/10.1186/s12872-020-01807-4<br>916 Vercellino, I., & Sazanov, L. A. (2022). The assembly, regulation and functi 915 516. https://doi.org/10.1186/s12872-020-01807-4 916 Vercellino, I., & Sazanov, L. A. (2022). The assembly, regulation and function of the 917 mitochondrial respiratory chain. Nature Reviews Molecular Cell Biology, 23(2), 141–161. 919 Vila-Sanjurjo, A., Smith, P. M., & Elson, J. L. (2021). Heterologous Inferential Analysis (HIA) and 918 https://doi.org/10.1038/s41580-021-00415-0 920 Other Emerging Concepts: In Understanding Mitochondrial Variation In Pathogenesis: 921 There is no More Low-Hanging Fruit. In V. Weissig & M. Edeas (Eds.), *Mitochondrial*<br>922 Medicine: *Volume 3: Manipulating Mitochondria and Disease- Specific Approaches* (pp.<br>923 203–245). Springer US. https://doi.org/ 922 Medicine: Volume 3: Manipulating Mitochondria and Disease- Specific Approaches (pp.<br>923 203–245). Springer US. https://doi.org/10.1007/978-1-0716-1270-5\_14<br>924 von Elm, E., Altman, 923 203–245). Springer US. https://doi.org/10.1007/978-1-0716-1270-5\_14 925 (2007). The Strengthening the Reporting of Observational Studies in Epidemiology 926 (STROBE) statement: guidelines for reporting observational studies. *The Lancet, 370*(9596),<br>1453–1457. https://doi.org/10.1016/S0140-6736(07)61602-X<br>928 Vallace, D. C. (2015). Mitochondrial DNA Variation in Human Radi 927 1453–1457. https://doi.org/10.1016/S0140-6736(07)61602-X 928 Wallace, D. C. (2015). Mitochondrial DNA Variation in Human Radiation and Disease. *Cell,*<br>929 *163*(1), 33–38. https://doi.org/10.1016/j.cell.2015.08.067<br>930 Wallace, D. C. (2018). Mitochond 929 163(1), 33–38. https://doi.org/10.1016/j.cell.2015.08.067 930 Wallace, D. C. (2018). Mitochondrial genetic medicine. *Nature Genetics, 50*(12), 1642–1649.<br>931 https://doi.org/10.1038/s41588-018-0264-z<br>932 Wang, J., Tomar, D., Martin, T. G., Dubey, S., Du 931 https://doi.org/10.1038/s41588-018-0264-z 933 M. G., Myers, V. D., Merali, S., Merali, C., Lemster, B., McTiernan, C. F., Khalili, K., Madesh,

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

